South Korea · Delayed Price · Currency is KRW J2KBIO Statistics
Total Valuation
J2KBIO has a market cap or net worth of KRW 55.20 billion. The enterprise value is 46.34 billion.
| Market Cap | 55.20B |
| Enterprise Value | 46.34B |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
J2KBIO has 5.85 million shares outstanding. The number of shares has increased by 1.86% in one year.
| Current Share Class | 5.85M |
| Shares Outstanding | 5.85M |
| Shares Change (YoY) | +1.86% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 62.10% |
| Owned by Institutions (%) | n/a |
| Float | 2.21M |
Valuation Ratios
The trailing PE ratio is 9.49.
| PE Ratio | 9.49 |
| Forward PE | n/a |
| PS Ratio | 1.26 |
| PB Ratio | 1.51 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | 11.45 |
| P/OCF Ratio | 10.61 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.75, with an EV/FCF ratio of 9.61.
| EV / Earnings | 7.97 |
| EV / Sales | 1.06 |
| EV / EBITDA | 5.75 |
| EV / EBIT | 7.13 |
| EV / FCF | 9.61 |
Financial Position
The company has a current ratio of 4.11, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.11 |
| Quick Ratio | 3.14 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | 0.21 |
| Interest Coverage | 151.56 |
Financial Efficiency
Return on equity (ROE) is 16.91% and return on invested capital (ROIC) is 20.23%.
| Return on Equity (ROE) | 16.91% |
| Return on Assets (ROA) | 10.24% |
| Return on Invested Capital (ROIC) | 20.23% |
| Return on Capital Employed (ROCE) | 17.26% |
| Weighted Average Cost of Capital (WACC) | 5.84% |
| Revenue Per Employee | 812.95M |
| Profits Per Employee | 107.66M |
| Employee Count | 54 |
| Asset Turnover | 1.11 |
| Inventory Turnover | 6.97 |
Taxes
In the past 12 months, J2KBIO has paid 1.19 billion in taxes.
| Income Tax | 1.19B |
| Effective Tax Rate | 16.96% |
Stock Price Statistics
The stock price has increased by +3.74% in the last 52 weeks. The beta is 0.30, so J2KBIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +3.74% |
| 50-Day Moving Average | 9,090.40 |
| 200-Day Moving Average | 8,443.10 |
| Relative Strength Index (RSI) | 47.72 |
| Average Volume (20 Days) | 100,727 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, J2KBIO had revenue of KRW 43.90 billion and earned 5.81 billion in profits. Earnings per share was 994.44.
| Revenue | 43.90B |
| Gross Profit | 17.40B |
| Operating Income | 6.50B |
| Pretax Income | 7.00B |
| Net Income | 5.81B |
| EBITDA | 8.06B |
| EBIT | 6.50B |
| Earnings Per Share (EPS) | 994.44 |
Balance Sheet
The company has 9.85 billion in cash and 989.70 million in debt, with a net cash position of 8.86 billion or 1,515.84 per share.
| Cash & Cash Equivalents | 9.85B |
| Total Debt | 989.70M |
| Net Cash | 8.86B |
| Net Cash Per Share | 1,515.84 |
| Equity (Book Value) | 36.57B |
| Book Value Per Share | 6,254.79 |
| Working Capital | 17.97B |
Cash Flow
In the last 12 months, operating cash flow was 5.20 billion and capital expenditures -383.73 million, giving a free cash flow of 4.82 billion.
| Operating Cash Flow | 5.20B |
| Capital Expenditures | -383.73M |
| Depreciation & Amortization | 1.56B |
| Net Borrowing | -279.89M |
| Free Cash Flow | 4.82B |
| FCF Per Share | 824.39 |
Margins
Gross margin is 39.64%, with operating and profit margins of 14.80% and 13.24%.
| Gross Margin | 39.64% |
| Operating Margin | 14.80% |
| Pretax Margin | 15.95% |
| Profit Margin | 13.24% |
| EBITDA Margin | 18.35% |
| EBIT Margin | 14.80% |
| FCF Margin | 10.98% |
Dividends & Yields
This stock pays an annual dividend of 250.00, which amounts to a dividend yield of 2.65%.
| Dividend Per Share | 250.00 |
| Dividend Yield | 2.65% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 26.00% |
| Buyback Yield | -1.86% |
| Shareholder Yield | 0.79% |
| Earnings Yield | 10.53% |
| FCF Yield | 8.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
J2KBIO has an Altman Z-Score of 7.02 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.02 |
| Piotroski F-Score | 5 |